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Background LMNA mutations are an important cause of cardiomyopathy often lead-
ing to cardiac arrhythmias, heart failure and even heart transplantation. An
increasing number of asymptomatic mutation carriers are identified, as family
members of the index patients are screened. Our aim was to study the disease
progression in asymptomatic LMNA mutation carriers and in patients with symp-
tomatic cardiolaminopathy by repeated spiroergometric testing in a prospective
clinical follow-up study.
Methods and Results We studied 26 LMNA mutation carriers once a year during
5 years up to 6 times by spiroergometry, clinical assessment, laboratory tests and
echocardiography. The 23 control subjects underwent clinical assessment and spir-
oergometry once. Twelve of the mutation carriers were asymptomatic, and 14
had some clinical manifestations of the mutation ranging from clinically relevant
rhythm disturbances to DCM and heart failure. Compared to controls, the symp-
tomatic carriers showed a higher slope of the ventilatory equivalent for CO2 ( _VE/
_VCO2 slope) and a lower fraction of end-tidal CO2 (FetCO2). The asymptomatic
mutation carriers also showed an increased ventilatory response to exercise during
the follow-up as indicated by increased _VE/ _VCO2 slope and decreased FetCO2.
Conclusions The study suggests that an increased ventilatory response during exer-
cise might reveal a preclinical manifestation of DCM in LMNA mutation carriers.
Introduction
LMNA mutations cause a variety of clinical phenotypes includ-
ing cardiomyopathy, lipodystrophy, muscular dystrophies,
neuropathy and progeria (Worman, 2012; Carboni et al.,
2013). In dilated cardiomyopathy, they are the aetiological
cause in about 5% of the cases (Parks et al., 2008; Lakdawala
et al., 2012). An increasing number of healthy mutation carri-
ers are in need of follow-up as disease-causing mutations are
identified in cardiomyopathy patients, and their family mem-
bers are screened for them (Perrot et al., 2006; Morales &
Hershberger, 2013). Cardiomyopathy-causing LMNA mutations
are thought to have a near-complete age-dependent pene-
trance (Van Berlo et al., 2005; Pasotti et al., 2010).
Spiroergometry or cardiopulmonary exercise testing is often
used to study patients with heart failure to assess maximal oxy-
gen uptake and functional capacity. Heart failure patients have
a lower oxygen consumption and an increased ventilatory
response indicated by an elevated _VE/ _VCO2 slope in spiroerg-
ometry (Poggio et al., 2010; Apostolo et al., 2012). Both of
these abnormalities suggest a poor prognosis (Nanas et al.,
2006; Poggio et al., 2010). Changes in lung stiffness, increased
dead-space ventilation due to mismatching of ventilation and
perfusion, increased exhaled CO2 level, decreased anaerobic
threshold and altered ventilatory regulation have been impli-
cated in the abnormal response to exercise (Koike et al., 1992;
Wasserman et al., 1997; Ponikowski et al., 2001; Agostoni et al.,
2002; Apostolo et al., 2012). Pulmonary oedema is also closely
associated with the changes in respiratory mechanics causing
reduced lung diffusion and injury to the alveolar–capillary
membrane (Apostolo et al., 2012).
The aim of this study was to investigate the disease progres-
sion by spiroergometric cardiopulmonary exercise test both in
patients with symptomatic cardiolaminopathy and in asymp-
tomatic LMNA mutation carriers during a follow-up-period of
5 years. We report the cardiopulmonary exercise test results
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of symptomatic and asymptomatic cardiomyopathy-causing
LMNA mutation carriers in a prospective follow-up study. To
our knowledge, similar studies in cardiomyopathy or lamin-
opathy have not been carried out earlier.
Methods
Patients and controls
The study included 26 carriers of five different LMNA mutations
known to cause cardiomyopathy (Table 1). The cardiac presen-
tation varied ranging from asymptomatic carriers with no signs
of heart disease in clinical assessment, ECG or echocardiogra-
phy to end-stage dilated cardiomyopathy and heart failure. Due
to this variation, we divided the study population into two
groups according to their phenotype. Patients with atrial fibril-
lation, sustained ventricular tachycardia, cardiac pacemakers or
ICDs, or dilated cardiomyopathy were included in the
symptomatic group. The asymptomatic group comprised of
individuals without clinically significant manifestations of
their LMNA mutation. The subjects did not switch groups
during the follow-up. The patients were recruited and studied
annually at Helsinki and Kuopio university hospitals between
2005 and 2010.
Twenty-three control individuals, without known heart dis-
ease, were matched for the whole study population for age,
sex and body mass index.
Methods
The patients were evaluated on an annual basis by clinical
examination, 12-lead electrocardiogram, echocardiography
and spiroergometry. Echocardiographic data were gathered
either from study visits or from hospital records. In addition,
data concerning the clinical cardiac follow-up and treatments
were collected from hospital records. The 23 control subjects
underwent ECG and spiroergometry once. Seventeen of them
were also studied with echocardiography.
Table 1 Characteristics of the control group, and the asymptomatic and symptomatic LMNA mutation carriers at baseline.
Control group
n = 23 %
Asymptomatic carriers
n = 12 %
Symptomatic carriers
n = 14 %
Age 4078 ( 139) 18–70 347 ( 137)
18–65
480 ( 118)
25–64
Men 10 435 4 333 5 357
Women 13 565 8 667 9 643
Height 173 ( 10)
154–193a
172 ( 12)
158–196a
171 ( 98)
157–187a
Weight 746 ( 121) 50-108a 709 ( 178)
51–105a
745 ( 140)
58–96a
BMI 249 ( 35) 198–334a 238 (39)
187–327a
253 (43)
204–366a
FEV1 (l) 35 ( 11) 20–55a 37 ( 10)
23–51a
32 ( 12)
16–55a
FEV1 (%) 901 ( 118) 65–111a 968 ( 68)
85–108a
853 ( 166)
63–114a
Regular leisure exercise 8 348 8 667 4 286
Smoker 4 174 1 83 2 143
Ex-smoker 3 130 1 83 3 214
Non-smoker 11 478 10 833 9 643
Smoking status NA 5 217
Mutations 0 3
Ala132Pro 2 2
Arg190Trp 0 1
G1493del 9 6
Ser143Pro 1 2
T1085Xdel
Medication
Betablocker 2 87 0 7 50
Warfarin 0 0 0 7 50
ACE inhibitor/AT blocker 2 87 0 7 50
Statin 2 87 0 1 71
Diabetes medication 2 87 0 0 0
Digoxin 0 0 0 2 143
Diuretic 2 87 0 2 143
Aldosterone antagonist 0 0 0 2 143
aMean ( SD) and range are given.
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Cardiorespiratory capacity was measured by a work-con-
ducted maximal exercise test with gas exchange analysis (spir-
oergometry) using an electrically braked bicycle ergometer
(Ergoselect ERG Ergometer; Marquette Hellige, Marquette
Medical Systems, Germany) and a breath-by-breath gas
exchange analysis system (Vmax Encore, Sensormedics, Yorba
Linda, CA, USA) with the test subject sitting upright. The ini-
tial workload was normally 40 W for women and 50 W for
men. The work load was then increased by 40 or 50 W,
respectively, at 3-min intervals until level 17–19/20 on the
Borg scale for perceived exertion was reached and respiratory
quotient RQ (= _VCO2/ _VO2) >10. Ventilatory anaerobic
threshold was assessed at the slope change of _VCO2 exceeding
_VO2, increase of _VE/ _VO2 compared to _VE/ _VCO2 and increase
of PetO2 versus PetCO2 (partial pressures of O2 and CO2 in
expiratory air) (Balady et al., 2010). Blood pressure was mea-
sured manually using a stethoscope and a sphygmomanometer
(Erka, Germany). Measurements were taken from the left arm
before exercise, at each exercise level, and 4 and 6 min after
exercise. A 12-lead ECG (Mason–Likar) was continuously
monitored and recorded during the exercise test using a com-
puterized device (CardioSoft version V65, GE Medical sys-
tems, Milwaukee, WI, USA). For measurement of respiratory
gases, a tightly attached face mask (Rudolph series 7910, Hans
Rudolph, Kansas City, MI, USA) with a dead space of 185 ml
was used. Arterial O2 saturation was assessed non-invasively
with two pulse oxymeters (Datex-Ohmeda 3900 and Datex-
Ohmeda 3800; Datex-Ohmeda, Louisville, CO, USA). One
sensor was attached to the earlobe and one to the left middle
finger. A mass flow sensor of the gas exchange device (Sensor-
medics) was used to measure forced expiratory volume in 1
second (FEV1) before exercise and to assess tidal volume and
minute ventilation during exercise. From the breath-by-breath
recordings, ventilatory and gas exchange variables were aver-
aged at 30-s intervals using computer-assisted equipment.
Echocardiography data from study visits or hospital records
from clinical follow-up visits were used. The study visit echo-
cardiography protocol included M-mode, two-dimensional
and Doppler analyses (Vivid 7; GE Medical Systems, Horten,
Norway). Individuals with left ventricular ejection fraction
<45% and surface area–normalized LVEDD >27 mm m2
were diagnosed with DCM (K€arkk€ainen et al., 2004).
The protocol (SPSS Inc, Chicago, IL, USA) was designed
and performed according to the principles of the Declaration
of Helsinki and was approved by the Ethical Committee of the
Helsinki University Central Hospital (decision number: Dnro
322/E5/03).
Statistical methods
IBM SPSS version 20.0 (SPSS Inc, Chicago, IL, USA) was
used for statistical analyses. Analysis of covariance with age,
gender, weight, height and the use of beta-blockers as cova-
riates was used to compare the results of the symptomatic
and asymptomatic patients to the controls for parameters
concerning oxygen uptake, heart rate or working capacity.
For echocardiography parameters and those spiroergometry
parameters measuring ventilation, beta-blockers were not
included as a covariate. Most of the variables were normally
distributed. For those few parameters that were not normally
distributed, the comparisons of the patients to the control group
giving statistically significant differences in covariance analysis
were confirmed using the nonparametric Mann–Whitney
U-test.
Paired t-test was used to compare the results within the
symptomatic and asymptomatic LMNA mutation carrier groups
during the follow-up. Bivariate correlation tests were per-
formed between some cardiologic and gas exchange variables,
Pearson correlation was used for normally distributed
parameters, and Spearman correlation if the parameters were
not normally distributed.
Results
The clinical characteristics of the mutation carriers and the
control individuals are reported in Table 1. The mean follow-
up times were 44 months for the entire study group, 51 (0–
63) months for the asymptomatic group and 38 (0–
66) months for the symptomatic group. Figure 1 plots FetCO2
and _VE/ _VCO2 slope against left ventricular ejection fraction in
all mutation carriers at baseline. Figure 2 shows the _VE/ _VCO2
slope values and Fig. 3 the FetCO2 values of symptomatic and
asymptomatic mutation carriers in follow-up.
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Figure 1 FetCO2 at maximal exercise (a) and _VE/ _VCO2 slope (b)
over left ventricular ejection fraction (LVEF) at the baseline examina-
tion. The asymptomatic LMNA mutation carriers are indicated with
circles and the symptomatic with triangles.
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Symptomatic LMNA mutation carriers
The results of the symptomatic LMNA mutation carriers are
reported in Table 2. The maximal heart rate during exercise
was lower in the symptomatic LMNA mutation carriers com-
pared to the control group throughout the follow-up, but the
difference was not statistically significant at all visits. The
symptomatic mutation carriers had a lower maximal working
capacity (per cent of predicted value) than the control group,
but the difference was not statistically significant at follow-up
visits 3 and 5. No further reduction from baseline in maximal
working capacity within the symptomatic LMNA mutation car-
rier group was seen. Anaerobic threshold was lower in this
group than in the control group, but the difference was not
statistically significant.
Breathing reserve did not differ from that of the control
groups. The ventilatory equivalents for O2 and CO2 ( _VEO2
and _VECO2) of the symptomatic carriers were significantly
higher than in the control group throughout the follow-up.
Similarly, FetCO2 was significantly lower in the symptomatic
carrier group than in the control group during the entire fol-
low-up. _VE/ _VCO2 slope was continuously higher in the symp-
tomatic group compared to the control group, and the
difference was statistically significant at all visits except fol-
low-up visit 3. The progression of _VE/ _VCO2 slope in each
individual symptomatic mutation carrier is plotted in Fig. 2.
Left ventricular ejection fraction was lower in the symptomatic
group than in the control group, the difference being statisti-
cally significant at baseline and follow-up visits 1 and 3.
Asymptomatic LMNA mutation carriers
The results of the asymptomatic LMNA carriers are reported
in Table 3. The asymptomatic group had a very similar
overall performance in spiroergometry compared to the
controls throughout the follow-up. Similarly, there was no
significant difference between the asymptomatic LMNA
carriers and the control group in LVEF measured by
echocardiography.
As the follow-up progressed, the maximal oxygen uptake
and oxygen pulse improved within the asymptomatic carrier
group. Using paired t-test, a statistically significant improve-
ment from baseline was seen towards the end of the follow-
up. However, comparing these parameters to the control
group did not show statistically significant differences.
The ventilatory equivalents of the asymptomatic carri-
ers did not systematically differ from the controls,
whereas _VE/ _VCO2 slope was significantly higher in the
asymptomatic carriers compared to the control group
from baseline to follow-up visit 2 (Fig. 2). The FetCO2
level was significantly lower in the asymptomatic carri-
ers compared to the control group from follow-up visits
1–4.
Dropouts
Only 4 of the initial 14 symptomatic carriers attended the last
follow-up visit. Two patients dropped out from follow-up
due to heart transplants. Two patients were unable to continue
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Figure 2 (a,b) _VE/ _VCO2 slope of the symp-
tomatic (a) and asymptomatic (b) LMNA
mutation carriers and the control group. (c).
The progression of _VE/ _VCO2 slope in follow-
up of the individual symptomatic mutation
carriers. The two individuals marked by trian-
gles received heart transplants after 3 and
6 months of the last follow-up visit they
attended.
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the follow-up due to ICDs. Three patients were lost to follow-
up due to the progression of their dilated cardiomyopathy.
Three patients finished the follow-up early because they were
enrolled to the study at a later stage. One of them underwent
spiroergometry three times, one-four times and one-five
times.
Six of the initial 12 asymptomatic carriers attended the
last follow-up visit. Three asymptomatic carriers were
enrolled at a later stage of the study and underwent follow-
up until follow-up visit 4. One asymptomatic carrier could
not attend the last spiroergometry due to a bone fracture,
and another one due to pregnancy. One participant was
enrolled at such a late stage that she only underwent spir-
oergometry once.
Discussion
We present the results of a 5-year follow-up study of symp-
tomatic and asymptomatic LMNA mutation carriers. The
symptomatic mutation carriers showed lower oxygen uptake,
a non-significantly lower anaerobic threshold and signs of
increased ventilation during exercise. A previously unde-
scribed finding in our study was that also the asymptomatic
carriers presented with signs of increased ventilation during
exercise, namely, elevated _VE/ _VCO2 slope and decreased Fet-
CO2.
Our study population of 26 LMNA mutation carriers is clini-
cally thoroughly studied. Fourteen patients were symptomatic
with dilated cardiomyopathy, arrhythmias and/or conduction
defects necessitating pacemakers, or atrial fibrillation. Twelve
mutation carriers were asymptomatic and showed no clinically
relevant abnormalities in echocardiography, nor hemodynami-
cally significant arrhythmias. As expected, signs of increased
ventilation during exercise typical for heart failure were found
in the symptomatic LMNA mutation carriers (Buller & Poole-
Wilson, 1990; Francis et al., 2000; Mezzani et al., 2009; Apos-
tolo et al., 2012). However, the asymptomatic LMNA mutation
carrier group also showed an increased ventilatory response
to exercise in terms of a decreased FetCO2 and increased
_VE/ _VCO2 slope.
A decreased oxygen uptake during cardiopulmonary exer-
cise testing is a known predictor of clinical outcome in heart
failure (Myers & Froelicher, 1991; Cahalin et al., 2013; Chase
et al., 2013). This is easily understandable as oxygen uptake is
a product of cardiac output and the difference between arterial
and venous oxygen (Myers & Froelicher, 1991). More recently
established variables with predictive power in heart failure
outcome are those measuring excessive ventilation during
exercise, namely the ventilatory equivalents, _VE/ _VCO2 slope
and FetCO2 (Francis et al., 2000; Cahalin et al., 2013; Chase
et al., 2013). The combination of an early anaerobic threshold
associated with a poor overall condition, increased dead-space
ventilation caused by increased overall ventilation, reduced
pulmonary perfusion causing ventilation-perfusion mismatch-
ing and an altered control of ventilation caused by enhanced
chemosensitivity are likely mechanisms to the increased venti-
latory response to exercise (Buller & Poole-Wilson, 1990; Ko-
ike et al., 1992; Sovij€arvi et al., 1992; Chua et al., 1997;
Wasserman et al., 1997; Ponikowski et al., 2001; Agostoni
et al., 2002; Apostolo et al., 2012).
As the symptomatic group comprised mainly patients with
dilated cardiomyopathy and systolic heart failure, an increased
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Figure 3 (a,b) The fraction of end-tidal CO2
level at maximal exercise (FetCO2) of the
symptomatic (a) and asymptomatic (b) LMNA
mutation carriers and the control group. (c)
The progression of FetCO2 in follow-up of
the individual symptomatic mutation carriers.
The two individuals marked by triangles
received heart transplants after 3 and
6 months of the last follow-up visit they
attended.
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ventilatory response to exercise was foreseeable. The similar
ventilatory response to exercise of the asymptomatic group,
however, was somewhat unexpected. The asymptomatic carri-
ers did not have increased dead-space ventilation, nor
decreased anaerobic threshold. Thus, increased chemosensitiv-
ity or incipient ventilation-perfusion mismatch might offer a
feasible mechanism. If a ventilation-perfusion mismatch was
present, it was slight because no hypoxaemia was present.
The mean LVEDD in the asymptomatic carriers was slightly,
non-significantly larger than in the controls, suggesting that
subclinical cardiomyopathy might also be a basis for the
finding.
_VE/ _VCO2 slope levels > 30–34 have been associated with
an increased risk of events and mortality in heart failure
patients (Chua et al., 1997; Francis et al., 2000; Gitt et al.,
2002; Arena et al., 2004; Balady et al., 2010; Cahalin et al.,
2013), whereas values between 20 and 30 are regarded as
normal (Mezzani et al., 2009; Balady et al., 2010). In our
study, the levels of _VE/ _VCO2 slope were between 30 and 34
in the symptomatic mutation carrier group and between 27
and 30 in the asymptomatic mutation carrier group. However,
the _VE/ _VCO2 slope values presented here are not directly
comparable with the mortality studies quoted above as they
evaluated the power of spiroergometric indices to predict
events and mortality in heart failure patients after a single
spiroergometry. We are not aware of other studies in which
cardiomyopathy patients or heart failure patients have been
tested repeatedly using spiroergometry for several years.
There has been some controversy on the measurement tech-
nique of _VE/ _VCO2 slope (Tabet et al., 2003; Mezzani et al.,
2009). We measured the initial part of the slope ignoring the
part turning nonlinear towards the end of exercise. The method
used here gives lower values than the measurement of the final
or overall _VE/ _VCO2 slope (Tabet et al., 2003). It is also consid-
ered more physiological, which is why it is recommended in a
recent American Heart Association guideline (Balady et al.,
2010). Furthermore, using the initial part of the slope is proba-
bly more suitable for repeated testing than measuring the final
_VE/ _VCO2 slope, which is more dependent on reaching maximal
exercise and may therefore vary in a clinical material.
Some patients in the symptomatic group dropped out of
the study due to a worsening clinical condition, whereas the
patients attending the entire follow-up were in better clinical
condition. This explains why the results of the symptomatic
carrier group appear to improve at follow-up visits 3–5.
Towards the end of the follow-up, the cardiac performance
of the asymptomatic mutation carrier group improved as mea-
sured by the oxygen pulse and oxygen uptake. Dropout does
not offer an explanation to this, as reaching the final 5th fol-
low-up visit was not affected by clinical condition in this
group. It may be that learning about their cardiomyopathy-
causing LMNA mutation and regular follow-up and spiroergo-
metric tests could have encouraged the asymptomatic carriers
to exercise more. In addition, the study group got more
familiar with the spiroergometry method, which might have
made the testing slightly easier and diminished anxiety caused
by it.
Dropout of patients caused difficulties in the statistical test-
ing as repeated-measurement tests were not applicable. There-
fore, analysis of covariance was used. The comparisons were
not independent comparisons of multiple variables, but
instead repeated measurements of the same subjects, which is
why Bonferroni correction was not applicable here. The con-
trol group underwent clinical exercise testing only once,
which is a weakness in our study.
This is a clinical prospective follow-up study on a geneti-
cally defined cardiomyopathy. A lower oxygen uptake and an
enhanced ventilatory response during exercise typical to heart
failure were found in the symptomatic LMNA mutation carrier
group. Also the asymptomatic LMNA mutation carriers showed
signs of excessive ventilation during exercise, namely
increased _VE/ _VCO2 slope and decreased FetCO2. Our findings
suggest that increased ventilation during exercise may be a
subclinical sign of cardiomyopathy in otherwise healthy LMNA
mutation carriers.
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